Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Gilead Sciences Inc (GILD)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Gilead's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
68.86 +1.59    +2.36%
28/01 - Closed. Currency in USD ( Disclaimer )
After Hours
67.27
-1.59
-2.31%
23:41:34 - Real-time Data
  • Volume: 11,497,350
  • Bid/Ask: 68.70 / 68.95
  • Day's Range: 67.02 - 68.87
Type:  Equity
Market:  United States
ISIN:  US3755581036 
CUSIP:  375558103
Gilead 68.86 +1.59 +2.36%
BearishBullish
Start Date Username Call Open Rate End Date Chg. %
Jan 26, 2022 David Santorsola   67.45 +2.09%
Jan 24, 2022 Donald Wilson   67.51 +2.00%
Jan 24, 2022 Financial Advisors   68.09 +1.13%
Jan 24, 2022 Miguel Luaces   68.48 +0.55%
Jan 19, 2022 Георгий Феодориди   69.91 Jan 24, 2022 @ 68.91 -1.43%
Jan 18, 2022 Hassen machat   70.49 -2.31%
Jan 12, 2022 fabrizio rossi   72.00 -4.36%
Jan 11, 2022 Marco Denna   72.44 Jan 17, 2022 @ 71.77 -0.92%
Jan 11, 2022 Ariel Brizuela   72.03 -4.40%
Jan 11, 2022 jack sich   71.63 Jan 17, 2022 @ 71.77 -0.20%
Jan 10, 2022 Şafak Tulgar   71.81 Jan 17, 2022 @ 71.77 +0.06%
Jan 10, 2022 Grietje Brazerol   72.06 -4.44%
Jan 06, 2022 Mehmet Yılmaz   71.76 Jan 28, 2022 @ 68.86 -4.04%
Jan 04, 2022 Calzeitor AC   72.72 Jan 28, 2022 @ 68.86 -5.31%
Jan 03, 2022 Johann Kulikovski   72.33 Jan 10, 2022 @ 71.75 -0.80%
Jan 03, 2022 지연 한   71.99 Jan 28, 2022 @ 68.86 -4.35%
Dec 30, 2021 Sergey Ulianov   73.36 Jan 21, 2022 @ 68.51 +6.61%
Dec 30, 2021 아실 이   73.57 Jan 21, 2022 @ 68.51 -6.88%
Dec 30, 2021 正孝 奥   73.74 Jan 21, 2022 @ 68.51 -7.09%
Dec 30, 2021 thiago alm   73.83 Jan 21, 2022 @ 68.51 -7.21%
Dec 29, 2021 Salman Azhar   73.36 Jan 21, 2022 @ 68.51 +6.61%
Dec 29, 2021 Johann Kulikovski   73.37 Jan 03, 2022 @ 72.21 -1.58%
Dec 29, 2021 Malice Palace   73.13 Jan 21, 2022 @ 68.51 -6.32%
Dec 28, 2021 Gonzalo De La Cierva   72.85 Jan 21, 2022 @ 68.51 -5.96%
Dec 28, 2021 Jan Poelaert   73.21 Jan 21, 2022 @ 68.51 -6.42%
Dec 28, 2021 Villy Prost   73.12 Jan 21, 2022 @ 68.51 -6.30%
Dec 28, 2021 Anastasios Tatarakis   73.30 Jan 21, 2022 @ 68.51 -6.53%
Dec 27, 2021 Antoni fermos   72.57 Jan 21, 2022 @ 68.51 -5.59%
Dec 27, 2021 Vicent Sales   72.30 Jan 21, 2022 @ 68.51 -5.24%
Dec 23, 2021 Alexey Morev   72.67 Jan 14, 2022 @ 71.77 -1.24%
Dec 23, 2021 Maverick Trading   72.42 Dec 27, 2021 @ 72.43 +0.01%
Dec 22, 2021 ENRIQUE LOPEZ M   72.14 Jan 14, 2022 @ 71.77 -0.51%
Dec 22, 2021 Ruski Gmnz   71.90 Jan 14, 2022 @ 71.77 -0.18%
Dec 21, 2021 Andrea Perrucchietti   71.82 Dec 27, 2021 @ 72.43 -0.85%
Dec 20, 2021 Alexandra Kovalenko   72.09 Dec 27, 2021 @ 72.43 +0.47%
Dec 17, 2021 marco baroni   72.01 Dec 20, 2021 @ 71.88 -0.18%
Dec 17, 2021 Salvo Tux   72.28 Jan 07, 2022 @ 71.26 -1.41%
Dec 16, 2021 Andrea Tripalo   72.71 Jan 07, 2022 @ 71.26 -1.99%
Dec 16, 2021 Gio Mal   72.65 Jan 07, 2022 @ 71.26 -1.91%
Dec 16, 2021 Chủng Phan   72.14 Jan 07, 2022 @ 71.26 -1.22%
Dec 15, 2021 Виталий Лебедев   70.44 Jan 07, 2022 @ 71.26 +1.16%
Dec 15, 2021 almir ramic   70.19 Dec 15, 2021 @ 70.22 +0.04%
Dec 15, 2021 진호 김   70.38 Dec 20, 2021 @ 71.88 -2.13%
Dec 14, 2021 Alejandro Baeza   70.53 Jan 07, 2022 @ 71.26 +1.04%
Dec 14, 2021 Duy Quang Tạ   70.21 Jan 07, 2022 @ 71.26 +1.50%
Dec 13, 2021 Tuan Le   70.59 Jan 07, 2022 @ 71.26 -0.95%
Dec 13, 2021 Werner Straudi   70.57 Dec 20, 2021 @ 71.88 +1.86%
Dec 10, 2021 진호 김   70.53 Dec 13, 2021 @ 70.39 -0.20%
Dec 09, 2021 jack sich   70.64 Dec 13, 2021 @ 70.39 -0.35%
Dec 08, 2021 Eduardo Farray   69.14 Dec 31, 2021 @ 72.61 +5.02%
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GILD Comments

Write your thoughts about Gilead Sciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Oc Masai
Oc Masai Apr 27, 2021 7:54
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good job GILD. bullish move forward
Ashraf Elgendy
Ashraf Elgendy Mar 07, 2021 13:03
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Kite, a unit of Gilead Sciences (GILD),has announced that theFDA has granted approval for its T cell immunotherapy Yescarta (axicabtagene ciloleucel) for a certain category of adults...
RM RM
RM RM Mar 01, 2021 21:53
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Up Again
Ken Laing
Ken Laing Oct 23, 2020 18:43
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Time to load up before the big rise coming next week
Iggy Maldon
Iggy Maldon Jul 30, 2020 20:22
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Classic pump n’ dump. What a shambles
RM RM
RM RM May 28, 2020 22:24
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Will reach above 95
SAGAR AGARWAL
SAGAR AGARWAL May 15, 2020 14:52
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good time to accumulate.
Khizer Malik
Khizer Malik May 14, 2020 11:04
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Gilead will be supplying remdesivir to 127 countries starting next week! Also backed by big government organisations including donald trump. Good investmenr
Willy Chin
Willy Chin Apr 23, 2020 18:14
Saved. See Saved Items.
This comment has already been saved in your Saved Items
High chance to be trading above 90, good long stock
Viktor Veselý
Viktor Veselý Apr 12, 2020 7:48
Saved. See Saved Items.
This comment has already been saved in your Saved Items
By Deena Beasley(Reuters) - More than two-thirds of severely ill COVID-19 patients saw their condition improve after treatment with remdesivir, an experimental drug being developed by Gilead Sciences Inc., according to new data based on patient observation.The analysis, published on Friday by the New England Journal of Medicine, does not detail what other treatments the 61 hospitalized patients were given and data on eight of them were not included -- in one case because of a dosing error.
Michal Hartman
Michal Hartman Mar 27, 2020 14:12
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Gilead has ebola medical called remdesivir, currently seems to be successfull also in treating covid, final study should be available end of March
oliver cheek
oliver cheek Mar 10, 2020 14:38
Saved. See Saved Items.
This comment has already been saved in your Saved Items
not if they dont find a vaccine. it will be condidered a waste of time and money and the stock will drop.
Alana Ashley
Alana Ashley Mar 06, 2020 20:32
Saved. See Saved Items.
This comment has already been saved in your Saved Items
gild and regn is working out on covid19 vaccine. both price getting higher as they promise to work it out. they will boom once they found the vaccine
jordan odan
jordan odan Jul 08, 2019 12:53
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buy position lets go profit by jordan
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email